Eris Lifesciences has informed stock exchanges about its management participation in an upcoming investor conference scheduled for March 10, 2026. The pharmaceutical company filed the disclosure on March 05, 2026 under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Conference Details

The company's management will participate in the Investec India Promoter & Founder Conference 2026, which will be held in Mumbai through physical meetings.

Regulatory Compliance

Eris Lifesciences emphasized that the schedule remains indicative and subject to changes due to any unforeseen developments. The company stated it will refer only to publicly available documents during discussions and confirmed that no unpublished price sensitive information (UPSI) is intended to be discussed during the interactions.

Management Representation

Two senior management representatives will attend the conference on behalf of Eris Lifesciences. Mr. Amit Bakshi and Ms. Kruti Raval will engage with institutional investors and analysts through both individual and group meeting formats.

The disclosure was signed by Milind Talegaonkar, Company Secretary & Compliance Officer, ensuring proper regulatory compliance for the investor engagement activity.

Eris Lifesciences Limited has received regulatory fines from both major Indian stock exchanges for non-compliance with board composition requirements. The pharmaceutical company disclosed the penalties in a regulatory filing dated February 28, 2026, in accordance with SEBI disclosure norms.

Regulatory Action Details

Both BSE Limited and the National Stock Exchange of India Limited imposed identical fines on the company through letters dated February 27, 2026. The regulatory action stems from violations under Regulation 17(1) of the SEBI Listing Regulations.

Nature of Non-Compliance

The company clarified that the non-compliance arose due to the completion of an Independent Director's term, affecting the board composition requirements. This situation created a temporary gap in meeting the prescribed board structure mandated under SEBI regulations.

Eris Lifesciences has been proactively addressing the issue by screening suitable candidates for appointment as Independent Director to fill the anticipated vacancy. The company expressed confidence in reporting compliance on the matter in the near future.

Financial Impact Assessment

The regulatory penalties have minimal financial impact on the company's operations. The total monetary consequence remains limited to the combined penalty amount of ₹1.30 lakh imposed by both exchanges.

Company's Response and Commitment

Eris Lifesciences emphasized its commitment to ensuring full compliance with all applicable laws and regulatory requirements. The company has taken corrective measures to address the board composition issue and prevent similar occurrences in the future.

The disclosure was made in compliance with Regulation 30 of SEBI Listing Regulations, demonstrating the company's adherence to transparency requirements despite the regulatory setback.